Silence Therapeutics (NASDAQ:SLN) Price Target Cut to $35.00 by Analysts at Chardan Capital

Silence Therapeutics (NASDAQ:SLN) had its target price decreased by Chardan Capital from $55.00 to $35.00 in a report released on Friday morning,Benzinga reports. Chardan Capital currently has a buy rating on the stock.

Several other equities analysts have also recently issued reports on SLN. The Goldman Sachs Group decreased their price objective on Silence Therapeutics from $6.00 to $4.00 and set a “sell” rating for the company in a report on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and issued a $75.00 price target on shares of Silence Therapeutics in a report on Friday, March 7th. Morgan Stanley lowered their price objective on Silence Therapeutics from $49.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 5th. Finally, BMO Capital Markets cut their target price on shares of Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, March 4th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Silence Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $33.83.

Silence Therapeutics Trading Up 3.9 %

Shares of NASDAQ:SLN opened at $3.70 on Friday. Silence Therapeutics has a twelve month low of $1.97 and a twelve month high of $24.38. The company has a market cap of $110.74 million, a PE ratio of -2.36 and a beta of 1.20. The company’s 50 day moving average is $3.39 and its 200 day moving average is $6.57.

Silence Therapeutics (NASDAQ:SLN) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.42). Silence Therapeutics had a negative return on equity of 62.81% and a negative net margin of 342.00%. The business had revenue of $0.14 million during the quarter, compared to analyst estimates of $3.58 million. Equities research analysts predict that Silence Therapeutics will post -1.77 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Silence Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in SLN. JPMorgan Chase & Co. acquired a new stake in shares of Silence Therapeutics in the fourth quarter valued at about $26,000. Barclays PLC boosted its holdings in Silence Therapeutics by 83.8% in the 4th quarter. Barclays PLC now owns 6,126 shares of the company’s stock worth $42,000 after buying an additional 2,793 shares during the last quarter. GAMMA Investing LLC increased its stake in Silence Therapeutics by 609.2% during the 4th quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock worth $42,000 after buying an additional 5,233 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Silence Therapeutics during the fourth quarter valued at approximately $69,000. Finally, Virtus ETF Advisers LLC lifted its position in shares of Silence Therapeutics by 130.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company’s stock valued at $74,000 after acquiring an additional 6,098 shares in the last quarter. Hedge funds and other institutional investors own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.